Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Beta This is a new resource - your feedback will help us improve it.

Series: Audits of Medicaid Select Diabetes and Weight Loss Drugs

Announced on  | Last Modified on  | Series Number: SRS-A-26-013
Status
Active
Agency
Centers for Medicare and Medicaid Services

OBJECTIVE

Medicaid utilization of and gross spending on select diabetes and weight loss drugs have rapidly increased in recent years. The select diabetes drugs were approved to help control blood sugar levels for individuals with type 2 diabetes; however, these drugs are known to be used for weight loss. Most States cover these drugs to treat Medicaid enrollees with diabetes. Additionally, some States cover similar types of drugs that were approved for weight loss. We will identify national Medicaid utilization for select diabetes and weight loss drugs and select one or more States to review.

There is 1 project in this series.

Project titles will remain unpublished until projects are complete and reports are posted.

ACTIVE PROJECTS IN THIS SERIES (1)

Project WA-24-0036 • Announced on Mar 15, 2024

TIMELINE

  • March 15, 2024
    Series Number SRS-A-26-013 Assigned
  • March 15, 2024
    Project Announced

    Project WA-24-0036

  • Today
    1 Project In-Progress
  • Est FY2026
    Estimated Fiscal Year for Series Completion
Work Plan Type
Office of Audit Services
HHS Agencies
Centers for Medicare and Medicaid Services
Issue Areas
Departmental Operational Issues Food, Drug and Device Safety Prescription Drug Public Health Issues
Target Groups
-
Financial Groups
Medicare D